Robert Elsby

2.0k citations

25 papers · 1.6k indexed · h-index 20

Impact in

Pharmacology top 0.5%
- Pharmacogenetics and Drug Metabolism
- Drug-Induced Hepatotoxicity and Protection
Oncology top 5%
- Drug Transport and Resistance Mechanisms

Papers in ⓘ

Pharmacology 11
- Pharmacogenetics and Drug Metabolism 9
- Drug-Induced Hepatotoxicity and Protection 3
Oncology 17
- Drug Transport and Resistance Mechanisms 17

Co-authors: Katherine S. Fenner (4 shared papers)Dominic Surry (9 shared papers)Constanze Hilgendorf (1 shared paper)Neil R. Kitteringham (4 shared papers)Pradeep Sharma (6 shared papers)John Ashby (3 shared papers)Christopher E. Goldring (2 shared papers)James L. Maggs (3 shared papers)
Journals: Xenobiotica (3 papers)Drug Metabolism and Disposition (3 papers)Journal of Pharmacology and Experimental Therapeutics (2 papers)Clinical Pharmacology & Therapeutics (2 papers)PROTEOMICS (2 papers)
Partner nations: United Kingdom United States Singapore

In The Last Decade

Robert Elsby

25 papers receiving 1.5k citations

Peers

Countries citing papers authored by Robert Elsby

Since Specialization

Citations

This map shows the geographic impact of Robert Elsby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Elsby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Elsby more than expected).

Fields of papers citing papers by Robert Elsby

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Elsby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Elsby. The network helps show where Robert Elsby may publish in the future.

Co-authors

The 25 scholars most cited alongside Robert Elsby, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Robert Elsby Line = papers co-authored together Robert Elsby links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 25 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Intracellular Drug Concentrations and Transporters: Measurement, Modeling, and Implications for the Liver Clinical Pharmacology & Therapeutics ·Xiaoyan Chu, Ken Korzekwa, Robert Elsby, Katherine S. Fenner, Aleksandra Galetin, Yurong Lai, Pär Matsson, Aaron M. Moss, Swati Nagar, Gus R. Rosania, Jingwen Bai, Joseph W. Polli, Yuichi Sugiyama, Kim L. R. Brouwer	2013	193
2	Activation of hepatic Nrf2 in vivo by acetaminophen in CD-1 mice Hepatology ·Christopher E. Goldring, Neil R. Kitteringham, Robert Elsby, Laura E. Randle, Y Clément, Dominic P. Williams, Michael McMahon, John D. Hayes, Ken Itoh, Masayuki Yamamoto, Kevin B. Park	2004	168
3	Understanding the Critical Disposition Pathways of Statins to Assess Drug–Drug Interaction Risk During Drug Development: It's Not Just About OATP1B1 Clinical Pharmacology & Therapeutics ·Robert Elsby, Constanze Hilgendorf, Katherine S. Fenner	2012	163
4	Increased Constitutive c-Jun N-terminal Kinase Signaling in Mice Lacking Glutathione S-Transferase Pi Journal of Biological Chemistry ·Robert Elsby, Neil R. Kitteringham, Christopher E. Goldring, Cerys Lovatt, M. Chamberlain, Colin J. Henderson, C. Roland Wolf, B. Kevin Park	2003	128
5	Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect? European Journal of Clinical Pharmacology ·Bruce K. Birmingham, Sarah R. Bujac, Robert Elsby, Connie T. Azumaya, Cheryl Wei, Yusong Chen, Rogelio Mosqueda‐Garcia, Helen J. Ambrose	2015	120
6	Validation and application of Caco-2 assays for thein vitroevaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions Xenobiotica ·Robert Elsby, Dominic Surry, Veronica Smith, Alasdair J. G. Gray	2008	100
7	Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States European Journal of Clinical Pharmacology ·Bruce K. Birmingham, Sarah R. Bujac, Robert Elsby, Connie T. Azumaya, Julie Zalikowski, Yusong Chen, Kenneth Kim, Helen J. Ambrose	2015	98
8	Comparison of the Modulatory Effects of Human and Rat Liver Microsomal Metabolism on the Estrogenicity of Bisphenol A: Implications for Extrapolation to Humans Journal of Pharmacology and Experimental Therapeutics ·Robert Elsby, James L. Maggs, John Ashby, B. Kevin Park	2001	91
9	Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure Drug Metabolism and Disposition ·Robert Elsby, Paul Martin, Dominic Surry, Pradeep Sharma, Katherine S. Fenner	2015	81
10	Relative and absolute quantitative expression profiling of cytochromes P450 using isotope‐coded affinity tags PROTEOMICS ·Rosalind E. Jenkins, Neil R. Kitteringham, Christie L. Hunter, Sally Webb, Tony Hunt, Robert Elsby, Rod B. Watson, Dominic P. Williams, Stephen R. Pennington, B. Kevin Park	2006	58
11	Prediction of the in vivo OATP1B1-mediated drug–drug interaction potential of an investigational drug against a range of statins European Journal of Pharmaceutical Sciences ·Pradeep Sharma, Caroline Butters, Veronica Smith, Robert Elsby, Dominic Surry	2012	43
12	Mechanistic in vitro studies confirm that inhibition of the renal apical efflux transporter multidrug and toxin extrusion (MATE) 1, and not altered absorption, underlies the increased metformin exposure observed in clinical interactions with cimetidine, trimethoprim or pyrimethamine Pharmacology Research & Perspectives ·Robert Elsby, Stephen Chidlaw, Samuel Outteridge, Sarah Pickering, Amy Radcliffe, Rebecca Sullivan, Hayley Jones, Philip Butler	2017	37
13	Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies Drugs in R&D ·Paul Martin, Michael Gillen, James M. Ritter, David Mathews, Clive Brealey, Dominic Surry, S. Oliver, Victoria Holmes, Paul Severin, Robert Elsby	2016	34
14	Obstacles to the prediction of estrogenicity from chemical structure: assay-mediated metabolic transformation and the apparent promiscuous nature of the estrogen receptor Biochemical Pharmacology ·Robert Elsby, John Ashby, John P. Sumpter, A. N. Brooks, William D. Pennie, James L. Maggs, Paul Lefevre, J. Odum, Nicola Beresford, David M. Paton, B.Kevin Park	2000	34
15	Assessment of the Effects of Metabolism on the Estrogenic Activity of Xenoestrogens: A Two-Stage Approach Coupling Human Liver Microsomes and a Yeast Estrogenicity Assay Journal of Pharmacology and Experimental Therapeutics ·Robert Elsby, James L. Maggs, John Ashby, David M. Paton, John P. Sumpter, B. Kevin Park	2001	32
16	Protein expression profiling of glutathione S‐transferase pi null mice as a strategy to identify potential markers of resistance to paracetamol‐induced toxicity in the liver PROTEOMICS ·Neil R. Kitteringham, Helen Powell, Rosalind E. Jenkins, Jane Hamlett, Cerys Lovatt, Robert Elsby, Colin J. Henderson, C. Roland Wolf, Stephen R. Pennington, B. Kevin Park	2003	31
17	Validation of membrane vesicle-based breast cancer resistance protein and multidrug resistance protein 2 assays to assess drug transport and the potential for drug–drug interaction to support regulatory submissions Xenobiotica ·Robert Elsby, Veronica Smith, Lisa Fox, David M. Stresser, Caroline Butters, Pradeep Sharma, Dominic Surry	2011	28
18	In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug–drug interaction with methotrexate European Journal of Pharmaceutical Sciences ·Robert Elsby, Lisa Fox, David M. Stresser, Mark Layton, Caroline Butters, Pradeep Sharma, Veronica Smith, Dominic Surry	2011	24
19	Validation of cell-based OATP1B1 assays to assess drug transport and the potential for drug–drug interaction to support regulatory submissions Xenobiotica ·Pradeep Sharma, Victoria Holmes, Robert Elsby, Craig Lambert, Dominic Surry	2009	23
20	The use of bioreactors as in vitro models in pharmaceutical research Drug Discovery Today ·Maaria Ginai, Robert Elsby, Christopher J. Hewitt, Dominic Surry, Katherine S. Fenner, Karen Coopman	2013	19

About Robert Elsby

Robert Elsby is a scholar working on Pharmacology, Oncology, Pediatrics, Perinatology and Child Health, Biochemistry and Health, Toxicology and Mutagenesis, having authored 25 papers that have together received 1.6k indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (17 papers), Pharmacological Effects and Toxicity Studies (9 papers), Pharmacogenetics and Drug Metabolism (9 papers), Effects and risks of endocrine disrupting chemicals (3 papers), Glutathione Transferases and Polymorphisms (3 papers), Drug-Induced Hepatotoxicity and Protection (3 papers), Genomics, phytochemicals, and oxidative stress (3 papers) and Pregnancy and Medication Impact (3 papers). The work is most often cited by research in Pharmacology (551 citations), Oncology (729 citations), Pediatrics, Perinatology and Child Health (363 citations), Hepatology (94 citations) and Health, Toxicology and Mutagenesis (144 citations). Robert Elsby has collaborated with scholars based in United Kingdom, United States and Singapore. Frequent co-authors include Katherine S. Fenner, Dominic Surry, Constanze Hilgendorf, Neil R. Kitteringham, Pradeep Sharma, John Ashby, Christopher E. Goldring, James L. Maggs, B. Kevin Park and Bruce K. Birmingham. Their work appears in journals such as Xenobiotica, Drug Metabolism and Disposition, Journal of Pharmacology and Experimental Therapeutics, Clinical Pharmacology & Therapeutics and PROTEOMICS.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact